Venture groups switching to survival mode

The Washington Post examines a trend that may have a deep impact on biotechnology. With IPOs all but dead for now, venture capital groups have been forced to pump more and more money into their companies in order to keep them afloat. And that has been leaving less and less money to fund new companies that need their backing to get started. A decade ago it took an average of four years for a venture-backed firm to go public. Now it's 8.6 years.

"It's really a question of staying the course and surviving," said Roger Novak, general partner of Novak Biddle Venture Partners in Bethesda. "This is the worst we've seen."

- read the story from the Washington Post

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.